/Investor DB

Casdin Capital — 2018 Investments

5 investments dated 2018 · listed companies and verified rows first · show all

Generation Biogenerationbio.comFeb 2018 · $100M

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)

BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsAtlas VentureForesite CapitalWellington ManagementDeerfield Management CompanyF-Prime CapitalFidelity Investments+1 more

Lyralyrahealth.comin𝕏May 2018 · $45M

Lyra provides mental health care services through a network of evidence-based providers, combining clinical expertise with technology to deliver accessible, quality care for employers and health plans.

Digital HealthEnterprise SoftwareHealthtechHR TechMental HealthBurlingame, US

David Ebersman(Founder)inBob Kocher(Co-Founder and Board Member)inDena Bravata(Founder)Alethea Varra(Vice President of Clinical Care)inJennifer Schulz(Chief Executive Officer)Elaine Yang(Executive Officer)in

Co-investorsAdditionBreyer CapitalCoatue ManagementDragoneer Investment GroupDurable Capital PartnersFidelity Investments+10 more

Ventus AIventus.aiinJan 2018 · $100M

Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.

AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande, US

Maran Vedamanikam(CEO and Manager)Peter Qian(Co-founder & CEO)Vincent Lu(Co-founder & CTO)

Co-investorsSamsung NextAndreessen HorowitzWndrCoAlexandriaBiotechnology Value FundFonds de solidarité FTQ+5 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Lyra TechnologiesMagenta Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.